Drug Trial Radar · NCT05166889
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,132
Actual
Start
Jan 3, 2022
Primary completion
Jan 19, 2026
Study completion Mar 11, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TozorakimabDrug
Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
TozorakimabDrug
Administered subcutaneously tozorakimab Dose 2 through Week 52.
PlaceboDrug
Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.Time frame: over 52 weeks
Locations
212 sites in 21 countries. Site status is shown where the registry gives one.
Research Site
Huntsville, Alabama
Research Site
Mobile, Alabama
Research Site
Montgomery, Alabama
Research Site
Phoenix, Arizona
Research Site
Bakersfield, California
Research Site
Sacramento, California
Research Site
Boynton Beach, Florida
Research Site
Ormond Beach, Florida
Research Site
Plantation, Florida
Research Site
Meridian, Idaho
Research Site
Evergreen Park, Illinois
Research Site
Normal, Illinois
Research Site
Iowa City, Iowa
Research Site
Kansas City, Kansas
Research Site
Baton Rouge, Louisiana
Research Site
Zachary, Louisiana
Research Site
Baltimore, Maryland
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
Missoula, Montana
Research Site
Brick, New Jersey
Research Site
New York, New York
Research Site
The Bronx, New York
Research Site
Charlotte, North Carolina
Research Site
Durham, North Carolina
Research Site
Gastonia, North Carolina
Research Site
Fargo, North Dakota
Research Site
DuBois, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Sayre, Pennsylvania
Research Site
Rapid City, South Dakota
Research Site
Franklin, Tennessee
Research Site
Houston, Texas
Research Site
Kingwood, Texas
Research Site
Salt Lake City, Utah
Research Site
Burlington, Vermont
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Showing 40 of 212 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.